US 10952996
ALK5 inhibitors
granted A61KA61K31/4375A61K31/439
Quick answer
US patent 10952996 (ALK5 inhibitors) held by Theravance Biopharma R&D IP, LLC expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Theravance Biopharma R&D IP, LLC
- Grant date
- Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 20
- CPC classes
- A61K, A61K31/4375, A61K31/439, A61K31/4545, A61K31/4709